Table 1.
Clinical and histopathological parameters of patients with rectal tumor for the entire cohort as well as for the male and female subcohorts
| Variable | Total (n = 1,061) | Male (n = 599) | Female (n = 462) | p value |
|---|---|---|---|---|
| Median age, years | 67.0 (23–97) | 65.0 (23–94) | 70.0 (31–97) | n.s. |
| Karnofsky < 100% | 458 (43.7%)a | 224 (37.7%)b | 234 (51.5%)c | n.s. |
| Elevated CEA | 244 (41.4%)d | 143 (42.7%)e | 101 (39.6%)f | n.s. |
| Symptomatic | 970 (91.4%) | 551 (92.0%) | 433 (93.1%) | n.s. |
| Neoadjuvant therapy R-status | 166 (15.6%) | 111 (18.5%) | 55 (11.9%) | n.s. |
| R0 | 795 (74.9%) | 454 (75.8%) | 341 (73.8%) | n.s. |
| R1 | 22 (2.1%) | 6 (1.0%) | 16 (3.5%) | n.s. |
| R2 | 244 (23.0%) | 139 (23.2%) | 105 (22.7%) | n.s. |
| Mean LN yield | 15.2 (± 6.0) | 15.0 (± 5.9) | 15.5 (± 6.3) | n.s. |
| UICC | n.s. | |||
| UICC 0 | 17 (1.6%) | 8 (13%) | 9 (1.9%) | |
| UICC I | 246 (23.2%) | 151 (25.2%) | 95 (20.6%) | |
| UICC II | 208 (19.6%) | 116 (19.4%) | 92 (19.9%) | |
| UICC III | 252 (23.8%) | 141 (23.5%) | 111 (24.0%) | |
| UICC IV | 216 (20.4%) | 128 (21.4%) | 88 (19.0%) | |
| UICC xg | 122 (11.5%) | 55 (9.2%) | 67 (14.5%) | |
| T-category | n.s. | |||
| T0 | 56 (5.3) | 29 (4.8%) | 27 (5.8%) | |
| Tis | 17 (1.6%) | 8 (1.3%) | 9 (1.9%) | |
| T1 | 97 (9.1%) | 59 (9.8%) | 38 (8.2%) | |
| T2 | 245 (23.1%) | 143 (23.9%) | 102 (22.1%) | |
| T3 | 461 (43.4%) | 268 (44.7%) | 193 (41.8%) | |
| T4 | 163 (15.4%) | 55 (9.1%) | 57 (13.4%) | |
| Tx | 22 (2.1%) | 37 (6.2%) | 36 (7.8%) | |
| N-category | n.s. | |||
| N0 | 541 (51.0%) | 312 (52.1%) | 229 (49.6%) | |
| N1 | 191 (18.0%) | 111 (18.5%) | 80 (17.3%) | |
| N2 | 199 (18.8%) | 105 (17.5%) | 77 (16.7% | |
| N xg | 147 (13.9%) | 71 (11.9%) | 76 (16.4%) | |
| M-category | n.s. | |||
| M0 | 829 (78.1%) | 465 (77.6%) | 364 (78.8%) | |
| M1 | 216 (20.4%) | 128 (21.4%) | 88 (18.1%) | |
| M xg | 16 (1.5%) | 6 (1.0%) | 10 (2.2%) | |
| Grading | n.s. | |||
| G1 | 19 (1.8%) | 8 (1.3%) | 11 (2.4%) | |
| G2 | 712 (67.1%) | 403 (67.3%) | 310 (67.1%) | |
| G3 | 329 (31.0%) | 187 (31.2%) | 141 (30.5%) | |
| G4 | 1 (0.1%) | 1 (0.2%) | 0 |
LN = Lymph node; n.s. = not significant, CEA = carcinoembryonic antigen;
UICC = Union internationale contre le cancer.
a
Of n = 1,048 available.
b
Of n = 594 available.
c
Of n = 454 available
d
Of n = 590 available.
e
Of n = 334 available.
f
Of n = 255 available.
g
Not assessable.